Merit Medical Systems, Inc. (NASDAQ:MMSI - Get Free Report) insider Brian Lloyd sold 16,722 shares of the business's stock in a transaction that occurred on Monday, November 16th. The shares were sold at an average price of $86.33, for a total transaction of $1,443,610.26. Following the transaction, the insider owned 60,132 shares of the company's stock, valued at approximately $5,191,195.56. This represents a 21.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Merit Medical Systems Price Performance
NASDAQ MMSI traded down $1.08 during trading on Tuesday, hitting $85.27. 118,407 shares of the company's stock were exchanged, compared to its average volume of 785,371. The company has a market cap of $5.11 billion, a PE ratio of 32.05, a P/E/G ratio of 2.11 and a beta of 0.56. The company has a current ratio of 4.52, a quick ratio of 3.05 and a debt-to-equity ratio of 0.42. Merit Medical Systems, Inc. has a fifty-two week low of $59.74 and a fifty-two week high of $94.85. The stock's 50 day moving average price is $87.95 and its two-hundred day moving average price is $77.43.
Merit Medical Systems (NASDAQ:MMSI - Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The medical instruments supplier reported $1.12 EPS for the quarter, beating analysts' consensus estimates of $1.04 by $0.08. Merit Medical Systems had a return on equity of 14.12% and a net margin of 9.94%. The company had revenue of $416.24 million during the quarter, compared to analysts' expectations of $410.56 million. During the same period in the prior year, the company earned $0.92 EPS. Merit Medical Systems's revenue was up 8.4% compared to the same quarter last year. Research analysts expect that Merit Medical Systems, Inc. will post 3.86 EPS for the current year.
Analyst Upgrades and Downgrades
A number of brokerages have recently commented on MMSI. Needham & Company LLC lifted their price target on Merit Medical Systems from $101.00 to $106.00 and gave the company a "buy" rating in a research note on Friday, October 30th. Canaccord Genuity Group upped their price objective on Merit Medical Systems from $94.00 to $121.00 and gave the company a "buy" rating in a research note on Friday, October 30th. Weiss Ratings upgraded shares of Merit Medical Systems from a "hold (c)" rating to a "hold (c+)" rating in a report on Monday, October 12th. JPMorgan Chase & Co. raised their price objective on shares of Merit Medical Systems from $95.00 to $110.00 and gave the company an "overweight" rating in a report on Friday, October 30th. Finally, Raymond James Financial set a $104.00 target price on shares of Merit Medical Systems and gave the stock an "outperform" rating in a research report on Monday. Eight investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $105.91.
Get Our Latest Research Report on Merit Medical Systems
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Merit Medical Systems by 11.7% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 173,854 shares of the medical instruments supplier's stock valued at $12,055,000 after buying an additional 18,276 shares in the last quarter. Jupiter Topco LLC bought a new position in Merit Medical Systems in the second quarter worth approximately $1,908,000. Trillium Asset Management LLC acquired a new stake in Merit Medical Systems in the second quarter valued at approximately $6,105,000. Irenic Capital Management LP acquired a new stake in Merit Medical Systems in the second quarter valued at approximately $37,623,000. Finally, Quantinno Capital Management LP increased its holdings in shares of Merit Medical Systems by 200.3% during the first quarter. Quantinno Capital Management LP now owns 17,612 shares of the medical instruments supplier's stock valued at $1,214,000 after acquiring an additional 11,747 shares in the last quarter. 99.66% of the stock is owned by institutional investors and hedge funds.
About Merit Medical Systems
(
Get Free Report)
Merit Medical Systems develops, manufactures and markets medical devices used in diagnostic and interventional procedures. Its products support clinicians in areas including cardiology, radiology, oncology and endoscopy. The company's portfolio includes devices and accessories for vascular access, diagnostic and therapeutic procedures, drainage, biopsy and embolization. Merit serves hospitals, clinics and other healthcare providers through direct sales and distribution channels. Founded in 1987 and headquartered in South Jordan, Utah, Merit Medical serves customers in the United States and internationally.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Merit Medical Systems, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merit Medical Systems wasn't on the list.
While Merit Medical Systems currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.